[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541291":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":42,"collaborators":44,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":11,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":11,"overallStatus":31,"whyStopped":11,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"NYU Langone Health","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Lung uDCD Protocol","EXPERIMENTAL",null,[13],"Device: Lung uDCD Protocol",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DEVICE","The intervention is initiation of PEEP and supplemental oxygen, without requiring prior permission (e.g., for cases not having first person authorization for organ donation and organ donation for research), to offer lung donation opportunities for cases which would otherwise be ineligible in the U.S.",[9],[20],{"name":21,"affiliation":5,"role":22},"Stephen Wall, MD","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Carolyn Sidoti","CONTACT","646-987-1371","Carolyn.Sidoti@nyulangone.org",[30],{"facility":5,"status":31,"city":32,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":11},"RECRUITING","New York","10016","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-74.00597,40.71427,{"lat":40,"lon":39},{"type":43,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[45],{"name":46,"class":47},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100541291","transplanting-lungs-from-uncontrolled-donation-after-circulatory-death-100541291",false,"NCT06327945","Transplanting Lungs From Uncontrolled Donation After Circulatory Death","Transplanting Lungs From Uncontrolled Donation After Circulatory Death: An Early Phase Clinical Trial","Inclusion Criteria:\n\n* Patients waiting for lung transplants\n* Willing to participate in the research study\n\nExclusion Criteria:\n\n* Unable to be followed for 1 year after transplantation\n* Unable to provide written informed consent to participate in the research (or designate a surrogate)","ALL","18 Years",{"count":58,"type":59},24,"ESTIMATED","INTERVENTIONAL",[62],"NA","The study team developed an uncontrolled donation after circulatory death (uDCD) protocol that preserves lungs for just over 3 hours after death using positive end expiratory pressure (PEEP) and supplemental oxygen. The study will assess lung uDCD program safety by continuous review of operations\u002Fclinical records from each case activation and transplantation. Attrition outcomes include rates of initial and continued lung preservation, donation authorization, lung recovery, passing ex-vivo lung perfusion (EVLP) performance testing, and lung transplantation. Planned viability assessments also include macroscopic determination, radiology (X-ray), and fiber optic bronchoscopy before initiating EVLP. We expect \\~50% of lungs assessed with EVLP will be transplanted to meet sustainability targets. Safety outcomes include the primary outcome, primary graft dysfunction (PGD) grade III at 72 hours, and secondarily survival one year after transplantation.",[65],"Lung Transplantation","2025-02-25",{"date":68,"type":69},"2025-02-28","ACTUAL",{"date":71,"type":69},"2025-01-24",{"date":73,"type":59},"2028-06-30",{"name":5,"class":6},1]